Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28359864 | 0.91 | BACE1 (0.38) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL21157864 | 0.76 | LMNA (0.50) | BACE1ALDH1A1MAPTKCNH2KMT2A | |
| SCHEMBL1568276 | 0.75 | CYP19A1 (0.68) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL9673557 | 0.75 | AKR1B1 (0.45) | AKR1B1 | |
| SCHEMBL22438572 | 0.75 | BACE1 (0.41) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL38654772 | 0.75 | BACE1 (0.45) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL15657386 | 0.74 | CFTR (0.45) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL10834099 | 0.74 | PDK2 (0.50) | BACE1ALDH1A1MAPTKCNH2KMT2A | |
| SCHEMBL2308362 | 0.72 | GRIN1 (0.51) | BACE1CYP2C9BLMPMP22CACNA1F | |
| SCHEMBL9194271 | 0.72 | NPC1 (0.44) | MAPTHTR2ATSHRTDP1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149390-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2023-05-18 | — | — | US | disclosed |
| CN-114316447-A | TPV material for vehicle and preparation method and application thereof | 东风汽车集团股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113896685-A | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9540330-B2 | Oligomer-containing hydantoin compounds | NEKTAR THERAPEUTICS (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160251244-A1 | WATER TREATMENT SYSTEMS AND METHODS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-09-01 | — | — | US | disclosed |
| CN-103804108-B | A kind of method preparing primary amine | 沈阳药科大学 | 2016-08-03 | — | — | CN | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140039020-A1 | Oligomer-Containing Hydantoin Compounds | NEKTAR THERAPEUTICS (US) | 2014-02-06 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013001498-A1 | AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2013-01-03 | — | — | WO | disclosed |
| US-4524206-A | TREATMENT OF NERVOUS SYSTEM DISORDER; DRUG OVERDOSE REVERSAL | MEAD JOHNSON & COMPANY (US) | 1985-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | BACE1 2502/4885CYP2C9 50/4885BLM 2301/4885 |
| US-20210000958-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | BACE1 2502/4885CYP2C9 50/4885BLM 2301/4885 |
| US-20230149390-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | OPRD1, OPRM1, CHRNA1 | BACE1 1210/4885CYP2C9 986/4885BLM 3737/4885 |
| US-20140039020-A1 | Oligomer-Containing Hydantoin Compounds | HTT, NOD2, HAAO | BACE1 1442/4885CYP2C9 673/4885BLM 1154/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | BACE1 2502/4885CYP2C9 50/4885BLM 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.